Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes.

Background: Patients with cancer and acute ischemic stroke (AIS) face high rates of recurrent thromboembolism or death.

Objectives: To examine whether hematologic and embolic biomarkers soon after AIS are associated with subsequent adverse clinical outcomes.

Methods: We prospectively enrolled 50 adults with active solid tumor cancer and AIS at two hospitals from 2016 to 2020.

Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study.

Objective: The objective of this study was to examine the pathophysiology of ischemic stroke with cancer.

Methods: We conducted a prospective cross-sectional study from 2016 to 2020 at 2 hospitals. We enrolled 3 groups of 50 adult participants each.